Terveystalo Oyj provides occupational healthcare services in Finland, Sweden, and Estonia. It operates through three segments: Healthcare Services, Portfolio Businesses, and Sweden. The company offers general practice and specialist medical care, diagnostic, outpatient surgery, dental, and other adjacent services; healthcare outsourcing and staffing services; child welfare services; and oral health, social, ER, well-being, and primary healthcare and specialty care services, as well as imaging and laboratory tests. It also provides remote and digital, diagnostic and screening, therapy and rehabilitation, and occupational health; leasing of personnel, partnership solutions, and assessment of the need for care; and organizational management consulting and addiction prevention services. The company serves private individuals and families, corporate and consumer, insurance companies, and public sector customers. Terveystalo Oyj was founded in 2001 and is headquartered in Helsinki, Finland.…
Sirujäteille synkkä perjantai
Terveystalo (HEL: TTALO) is listed on Nasdaq Helsinki, where its shares trade in EUR. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 8,111 employees.
The shares were at 5.920 EUR on 20 November 2026, down 34.1% over 52 weeks. Its 52-week range is 5.850 EUR to 10.42 EUR: the price is 43.2% below the high and 1.2% above the low.
At a market capitalisation of 750.71M EUR, it trades at 12.9 times trailing earnings and 9.0 times forward earnings. The median trailing P/E of its 18 largest Medical Care Facilities peers is 23.8, a discount of 46% for TTALO. It pays a dividend yielding 10.85% (it pays out 142% of its earnings), against a median of 0.76% among the dividend payers in that peer group.
Terveystalo reports return on equity of 15.9%, an operating margin of 8.9% and revenue down 6.2% year over year.
Its debt exceeds its cash by 647.10M EUR, a debt-to-equity ratio of 0.99. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 3 analysts cover the stock; their mean price target of 7.167 EUR is 21.1% above the current price. The next earnings report is expected on 12 February 2027.